Series C✦ Frontier trackbit.bio

bit.bio programs stem cells into any human cell type at industrial scale

A Cambridge spinout whose opti-ox gene-engineering platform converts stem cells into consistent, batch-after-batch human cells — selling a 50-product ioCells catalogue to drug makers as an alternative to animal testing.

شركة كامبريدج الناشئة تحوّل الخلايا الجذعية إلى أي نوع من الخلايا البشرية بتقنية أوبتي-أوكس، وتبيع كتالوج آيو سِلز لشركات الأدوية بديلًا عن التجارب على الحيوانات.

Next →
  1. The Bottleneck

    What was broken?

    Drug discovery runs on cells that do not behave like human biology — animal models and inconsistent lab-grown cells fail to predict how a drug acts in people, so most candidates die late and expensively.

  2. The Move

    Why it worked

    Turned cell-making from craft into code: an AI-enabled discovery platform finds the transcription-factor recipes and patented opti-ox technology executes them, producing defined human cells with industrial purity and consistency.

  3. The Trap

    Battle scars

    Pivoting from therapeutics ambition to tools provider after the 2025 restructuring cost a quarter of staff; must now prove the platform business scales, manufacturing keeps up, and toxicology customers switch from animal models.

The problem

Most drugs fail because the cells they were tested on never behaved like a human body: animal models mistranslate, and lab-grown human cells vary batch to batch. Researchers who need a defined, reproducible human cell — a neuron, a muscle fibre, a liver cell — either cannot get one or cannot trust the one they get, and regulators are steadily pushing the industry toward human-relevant New Approach Methodologies over animal testing.

How it works

bit.bio, founded in 2016 by Dr Mark Kotter from his Cambridge University labs after his discovery of the opti-ox technology, industrializes cell programming. An AI-enabled discovery platform finds the transcription-factor combinations that define each cell type, and patented opti-ox converts iPSCs into those types with unprecedented purity, consistency, and scale. The ioCells catalogue — 50+ products including wild-type, disease-model, and CRISPR-ready cells — gives drug developers off-the-shelf human biology. After a 2025 strategic reset that wound down internal therapeutics work and cut about a quarter of staff, the company is a pure platform-and-tools provider under CEO Przemek Obloj.

Pain points

Unpredictive animal models that kill candidates late; irreproducible lab-grown cells; scarce access to rare or diseased human cell types; and toxicology workflows still built around animal testing just as regulators demand alternatives.

Business model

Catalogue sales of ioCells products to research and pharma customers, global scale-up of manufacturing operations, expansion into the toxicology market, and generating cell datasets for AI model training.

Challenges

The 2025 pivot traded moonshot therapeutics upside for tools-business discipline — now bit.bio must prove catalogue revenue and toxicology adoption grow fast enough to justify the platform bet, while deep-pocketed reagents incumbents defend their accounts.

Funding

  • Raised: $50M Series C led by M&G Investments (Jan 2026); earlier $103M Series B first close (Nov 2021, Arch Ventures, Tencent, others) and $41.5M Series A (Jul 2019).
  • Valuation: no public priced valuation (MISSING).

Latest — January 2026

bit.bio closed a $50M Series C led by M&G Investments to accelerate product development, scale global operations and manufacturing, enter the toxicology market, and generate datasets for AI training — its first raise since the 2025 restructuring.

Similar sparks

⚡️ PUBLIC✦ Frontier

Switzerland · 2026-07-01

CRISPR Therapeutics edits DNA to cure blood disease with a single treatment

A Swiss gene-editing company that turned CRISPR/Cas9 from lab tool into approved medicine — its one-shot therapy CASGEVY functionally cures sickle-cell disease and beta thalassemia, now cleared for children as young as two.

بالعربي

شركة سويسرية لتحرير الجينات حوّلت كريسبر من أداة مختبرية إلى دواء معتمد: علاجها كاسغيفي يشفي فقر الدم المنجلي والثلاسيميا بجرعة واحدة، وأُجيز للأطفال من عمر سنتين.

  • biotech
  • #frontier
⚡️ PUBLICUS$555.5M IPO (Dec 2020)

Canada · 2026-09-28

AbCellera discovers antibody drugs with an AI-powered engine

A Vancouver clinical-stage biotech that finds and develops antibody medicines — from target to manufactured candidate — for itself and pharma partners, after its Lilly-partnered COVID antibody made it Canada's biggest biotech IPO.

بالعربي

شركة تكنولوجيا حيوية في فانكوفر تكتشف أدوية الأجسام المضادة بمحرك مدعوم بالذكاء الاصطناعي لصالحها وشركائها من شركات الأدوية.

  • biotech
  • #canada
⚡️ LATE-STAGE-PUBLIC

China · 2026-02-26

BeOne Medicines makes targeted blood-cancer drugs that outsell Western rivals

Beijing-founded global oncology biotech behind Brukinsa, a BTK inhibitor for B-cell cancers: $5.3B revenue in 2025, triple-listed in New York, Hong Kong and Shanghai, renamed BeOne after redomiciling to Switzerland in 2025.

بالعربي

شركة أدوية أورام صينية عالمية طوّرت دواء بروكينسا لسرطانات الدم وحققت إيرادات 5.3 مليار دولار في 2025، وأعادت تسمية نفسها بي‌ون بعد انتقال مقرها إلى سويسرا.

  • biotech
  • #biotech
⚡️Spark playbook copied! Go build.